A Phase 3, Randomised, Double-blind Study to Compare the Efficacy, Safety, PK and Immunogenicity Between SB8 (Proposed Bevacizumab Biosimilar) and Avastin® in Subjects With Metastatic or Recurrent Non-squamous Non-small Cell Lung Cancer
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 06 Nov 2017
At a glance
- Drugs Bevacizumab (Primary)
- Indications Non-small cell lung cancer
- Focus Registrational; Therapeutic Use
- Sponsors Samsung Bioepis
- 18 Sep 2017 Status changed from recruiting to active, no longer recruiting.
- 31 Jul 2016 Status changed from not yet recruiting to recruiting.
- 07 Jun 2016 Planned initiation date changed from 1 May 2016 to 1 Jun 2016.